Investors Newsletter

Number 1 April 11, 2014

E-QURE
ELECTRIC QUICK ULCER REMEDY

This is the first newsletter for our future investors. We will update you periodically in conjunction with the formal releases we will be filing as a listed company.

We are currently preparing for the launch of our operation. We have just came back from a week in the USA to make sure all that is needed is ready for the launch.

We have finalized the FDA clinical trial design and concluded commercial terms with ABIA who is going to act as the trial CRO. Clinical trial is going to take place in Akron Ohio in 6 medical centers. Signing with ABIA is expected by the end of the month.

We are currently changing the name of the company from ADBI to E-QURE and expect to get clearance for it within a week.

For corporate legal and tax considerations, we are re-domiciling the company to Delaware. The company main office is going to be located in Connecticut with a wholly own subsidiary in Israel.

We are finalizing organization of the capital structure of the company. Prior to the fundraising, the company will have 15M shares outstanding.

Board of directors will be formally announced immediately before transfer of money to the company and will include prominent people from Israel and the USA. Name announcement will be made separately.

Advisory board will also be formally announced separately and will include medical professions from Israel and the USA.

The transfer of the Patents into the company is being completed these days and all assets will be operational by the end of the months.

The money that was collected in this fundraising is located in the two escrow accounts. Immediately after Passover, investors will receive the subscription agreement to sign, after which, the money will be transferred to E-QURE by the end of the April.

Investors should expect to receive their shares certificates two weeks after signing the subscription agreement.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE's reports filed from time to time with the Securities and Exchange Commission.

E-QURE Corp. 107 Renovah Circle, Stamford, CT 06905, USA.
www.e-qure.com.
info@e-qure.com